Understanding and Optimizing ASGR1-Dependent Liver Targeting
Liver-targeted drug delivery has become a cornerstone of modern therapeutic development, particularly for RNA-based medicines such as siRNAs and antisense oligonucleotides (ASOs). As GalNAc-conjugated therapeutics continue to advance through preclinical and clinical pipelines, demonstrating receptor-specific uptake has become increasingly important for generating robust and reproducible data.
The asialoglycoprotein receptor (ASGPR), highly expressed on hepatocytes, plays a central role in this process by mediating the internalization of GalNAc-conjugated molecules into liver cells. More recently, emerging therapeutic approaches such as Lysosome-Targeting Chimeras (LYTACs) have also leveraged ASGPR-mediated trafficking to enable targeted degradation of extracellular proteins.
For researchers developing these therapies, one challenge remains consistent: how can receptor-mediated uptake be confidently distinguished from alternative cellular internalization pathways?
Reliable cellular models are essential to validate ASGR1-dependent mechanisms, strengthen mechanistic studies, and build confidence in preclinical results.
The Solution: ASGR1 Knockout HepG2 Cell Line
The ASGR1 Knockout HepG2 Cell Line (Cat. #84118) from BPS Bioscience provides a well-characterized human hepatocyte model that lacks expression of ASGR1 (Asialoglycoprotein Receptor 1).
Generated using CRISPR/Cas9 genome editing in the HepG2 background, this ready-to-use cell line enables researchers to directly investigate the role of ASGR1 in the uptake, trafficking, and biological activity of liver-targeted therapeutics.
Whether validating GalNAc-conjugated delivery systems or studying emerging LYTAC technologies, this model provides a definitive ASGR1-negative control for mechanistic and translational research.
Key Features
- Human HepG2 liver cell background
- CRISPR/Cas9-mediated ASGR1 knockout
- Validated by genomic sequencing, flow cytometry, and internalization assays
- Mycoplasma-free
- Ready-to-use adherent cell line
- Suitable for mechanistic and translational studies
Applications
The ASGR1 Knockout HepG2 Cell Line is ideally suited for:
- Validation of GalNAc-mediated delivery platforms
- Development of siRNA therapeutics
- Antisense oligonucleotide (ASO) research
- LYTAC development and mechanism-of-action studies
- ASGR1 target validation
- Comparative uptake studies versus wild-type HepG2 cells
- Investigation of alternative hepatic uptake pathways
Who Can Benefit?
This model is particularly valuable for researchers working in:
- RNA therapeutics
- Liver-targeted drug delivery
- GalNAc conjugate development
- Targeted protein degradation (LYTACs)
- Drug discovery and translational research
- Hepatic receptor biology
Why Researchers Choose this Model?
The ASGR1 Knockout HepG2 Cell Line helps researchers:
- Demonstrate ASGR1-dependent uptake with confidence
- Differentiate receptor-mediated internalization from alternative uptake pathways
- Strengthen mechanism-of-action studies
- Generate more robust preclinical data
- Save time with a validated, ready-to-use human hepatocyte model
Quick Takeaway
Researchers developing GalNAc therapeutics, siRNAs, ASOs, or LYTACs need reliable models to confirm receptor-specific uptake.
The ASGR1 Knockout HepG2 Cell Line provides a validated human hepatocyte model that enables direct assessment of ASGR1-mediated internalization, helping generate more robust and reproducible preclinical data.
Loss of ASGR1 Prevents Cell Surface Expression of ASGR2
Expression of ASGR1 (left) in the ASGR2 (right) and Knowkout HepG2 Cell Line by flow cytometry.
Cell surface expression of ASGR2 in the ASGR1 Knockout HepG2 Cell Line by flow cytometry. The ASGPR complex present at the cell surface is composed of ASGR1 and ASGR2 subunits. Cells were stained with a PE-labeled anti-ASGR2 Recombinant Rabbit Monoclonal Antibody and analyzed by flow cytometry. Parental HepG2 cells are shown in blue, and ASGR1 Knockout HepG2 cells are shown in red. Unstained parental HepG2 cells are shown in yellow. As a control, parental HepG2 cells were stained with a PE-labeled Donkey anti-Rabbit IgG Antibody and are shown in green. The y-axis shows the % of cells, while the x-axis represents the fluorophore intensity. In the absence of ASGR1, ASGR2 is no longer detected on the cell surface.
ASGR1 Knockout Eliminates GalNAc Ligand Uptake
Uptake of a triantennary GalNAc-conjugated fluorescent ligand by ASGR1 Knockout HepG2 Cell Line.
The ASGPR complex ASGPR binds glycoproteins with a terminal galactose (Gal) or N acetylgalactosamine (GalNAc) and targets them for endocytosis. HepG2 parental cells or ASGR1 Knockout HepG2 cells were seeded in a 24-well plate at 50,000 cells per well. The next day, cells were treated with either 0, 100, or 500 nM tri-GalNAc-C5-AF647 (R&D Systems #7901), a fluorescent ASGPR ligand. After 1 hour incubation at 37°C, cells were harvested and washed before measuring fluorescence by flow cytometry. Mean fluorescence intensity represents the level of tri-GalNAc-C5-AF647 endocytosed by the cells. Bars represent the mean of 3 replicates performed on the same day, and error bars show the standard deviation. This data is representative of multiple independent experiments.
Need More Than a Cell Line? Accelerate Your Liver-Targeted Research
Developing liver-targeted therapeutics often requires more than the right cell model. From early discovery through preclinical research, Tebubio's scientific experts can support your programme with flexible Contract Research Organisation (CRO) services, including assay development, experimental design, mechanistic studies and bespoke preclinical research.
Whether you need a validated research model, scientific expertise or additional laboratory capacity, we're here to help move your project forward with confidence.
-
References
Article content created by Tebubio using courtesy materials provided by BPS Bioscience.